Starving on Ozempic? CagriSema Crushes Cravings + 22.7% Loss 💪

Hey man,

Remember that desperate 3am kitchen raid...

when Ozempic left you hollow as a drum?

Meet CagriSema—a worthy weight-loss drug for you to consider.

...it's a co-formulation of cagrilintide and semaglutide [12]

Kinda makes Ozempic look so 2021.

This isn't just another GLP-1...

It's a Navy Destroyer's precision laser... aimed at your hunger hormones.

The Amylin Advantage That Changes Everything

Amylin is a 37-amino-acid peptide. Discovered ~35 years ago. [2][9]

While Ozempic plays defense with just GLP-1...

CagriSema brings Mike Tyson in his prime... 

and Sugar Ray Robinson to the fight: [10] 🥊 

🎯 Semaglutide (the Ozempic part)

🎯 Cagrilintide (the game-changer)

Cagrilintide mimics amylin...

your body's "stop eating NOW" hormone...

that actually works WITH your brain's hunger centers. [2]

Has better glycemic control too. [9]

Think of it like this:

If Ozempic is a bouncer at the club door...

CagriSema is the bouncer PLUS the guy who turns off the music...

and kills the lights.

Party's over. Hunger's dead. 💀

Meet Rob, 47, A badass Kansas City, MO plumber... 👨‍🔧🔧 

but 256 pounds of frustration...

Ozempic got him down to 218...

then the hunger came roaring back like a wounded bear. 🐻

His wife found him eating Jif peanut butter from the jar at 2am...

tears streaming down his face.

"I felt like a failure."

Then he enrolled in the REDEFINE 1 trial... [11]

68 weeks later?

22.7% of his body weight... GONE. [3]

From 256 to 198 pounds.

No midnight raids.

No white-knuckling through hunger.

Just... freedom.

The Science That Silences Your Stomach

Here's what the data screams:

REDEFINE 1 Trial Results: [11]

• 22.7% weight loss at 68 weeks (vs 16.1% with semaglutide alone)

• Blood pressure dropped like a rock [7]

• Participants reported feeling "liberated from food obsession"

Type 2 Diabetics Get Even MORE in REDEFINE 2: [8]

• 13.7% body weight vanished

• HbA1c locked down tight, with 73.5% of patients hitting normal range targets of 6.5% or less.

Phase 2 Head-to-Head: [2]

CagriSema DEMOLISHED solo semaglutide:

• 15.6% loss vs 5.1% at just 32 weeks

• Triple the weight loss percentage

The Hunger-Crushing Mechanism

Listen up...

This is where it gets good for ya: [2]

Step 1: Semaglutide hits your GLP-1 receptors → Slows stomach emptying → Tells your brain "you're full" [4]

Step 2: Cagrilintide activates amylin pathways → Blocks hunger signals at the source → Makes you forget food exists

Step 3: This unique combo creates synergy → 1 + 1 = 3 effect → Appetite suppression on Superman mode. 🦸‍♂️

One trial participant described it perfectly:

"It's like someone finally found my appetite's OFF switch." [6]

Blood Pressure Bonus Nobody Expected

Here's what shocked researchers... [7]

CagriSema doesn't just melt fat...

It's a cardiovascular Iron Man:

📉 Systolic BP: -10.9 mmHg average reduction

📉 Diastolic BP: -5.4 mmHg average reduction

📉 Medication: Nearly 40% of patients decreased or completely stopped their blood pressure meds.

Translation?

Your heart gets younger while your waistline shrinks.

Real Numbers from Real People

The clinical reviews are unanimous... [6]

At the maximum 2.4 mg / 2.4 mg CagriSema weekly dose: [3][8][10]

• Week 68: -22.7% body weight.

The weight loss accelerates steadily...

instead of plateauing early like with older therapies.

Who Wins CagriSema vs. The Old Guard?

Based on current data: [5][6]

✅ Better than Ozempic/Wegovy: Significantly more weight loss (22.7% vs 16.1% in trials).

✅ Better for Diabetics: Achieved 14.2% weight loss…

compared to just 10.2% for high-dose Ozempic…

in a 68-week diabetic head-to-head.

The only thing that might beat it?

Retatrutide's triple-receptor assault...

(We already covered Retatrutide here... ) 😉

The Freedom You've Been Hunting For

Imagine this:

Walking past the Dunkin' Donuts without a second glance... 🍩🍩🍩 

Forgetting to eat lunch because you're not thinking about food...

Your wife asking "aren't you hungry?" and honestly answering

"nope"...

That's not willpower.

That's CagriSema. [1][2]

Your Next Move

CagriSema just completed Phase 3 REDEFINE trials...

FDA approval expected by late 2026... [3][14]

But here's the thing:

Smart men are already asking their doctors about...

compassionate use programs...

Getting on waiting lists...

Positioning themselves for Day 1 access.

While your buddies struggle with Ozempic rebounds... [13]

You could be riding the dual-agonist wave to freedom.

Want the CagriSema Combat Guide?

Reply DUAL POWER and I'll send:

• Trial enrollment criteria

• Dosing protocols from REDEFINE

• Questions to ask your endocrinologist

• Early access strategies

Don't just lose weight.

Lose the food obsession.

To your freedom,

Mens Health Secrets 
–Live Past 100

P.S. Next email drops the mother lode... Head-to-head comparison of ALL the heavy hitters. Which drug wins for YOUR specific situation? The answer might surprise you... 🎯

P.P.S. Always consult with your doctor or specialist before starting any weight-loss medication. This newsletter is for education and entertainment only... Edutainment. We assume no liability.

P.P.P.S. >>> Go here to subscribe to our Mens Health Secrets YouTube Channel if you haven't yet…. leave a comment… and level up your Mens Health knowledge to live longer.

P.P.P.P.S. New Skool group: FREE. FREE. FREE... for life through Q2. Reply "TRIBE." Your Mens Health Secrets community is waiting.

Medical References:

CagriSema – GLP-1 + amylin combo (emerging)

[1] Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736-1748. https://doi.org/10.1016/S0140-6736(21)00845-X

[2] Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015). Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews, 67(3), 564-600. https://doi.org/10.1124/pr.115.010629

[3] Ahmed M, Hassan M, Tahir M, Hussain M, Islam F, Khan GT, Ahsan M, Bin Shafiq S, Ibrahim A, Uddin A, Waqas SA. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab. 2026 Mar 16. https://doi.org/10.1111/dom.70667. Epub ahead of print. PMID: 41834765.

[4] Gadelmawla AF, Hammad N, Atta K, Diaa A, Abouzkaly F, Soni K, Kelkar R, Agrawal SP, Ahmed R, Jain H, Passey S, Aronow WS. CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Am J Cardiol. 2026 Feb 26:S0002-9149(26)00085-8. https://doi.org/10.1016/j.amjcard.2026.02.030. Epub ahead of print. PMID: 41759565.

[5] Frias JP, Bastyr EJ 3rd, Vignati L, Tschöp MH, Schmitt C, Owen K, Christensen RH, DiMarchi RD. The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metab. 2017 Aug 1;26(2):343-352.e2. https://doi.org/10.1016/j.cmet.2017.07.011. PMID: 28768173.

[6] Anastasiou IΑ, Argyrakopoulou G, Dalamaga M, Kokkinos A. Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data. Curr Obes Rep. 2025 Apr 11;14(1):34. https://doi.org/10.1007/s13679-025-00623-1. PMID: 40210807; PMCID: PMC11985575.

[7] Verma, S., Böttcher, M., Dicker, D., Rubino, D., Sbraccia, P., ... & Sørrig, R. (2026). CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1. Hypertension, 83(2), e26055. https://doi.org/10.1161/HYPERTENSIONAHA.125.26055 (REDEFINE 1: BP reduction alongside 20%+ weight loss.)

[8] Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., ... & Buse, J. B. (2025). Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine, 393(7), 648-659. https://doi.org/10.1056/NEJMoa2502082 (Phase 3: 16% loss in T2D over 68 weeks.)

[9] Somar Hadid, R., Haddad, F., & Klein, S. (2025). Advancing diabetes management and glycemic control while exploring CagriSema's impact on obesity management. Cardiology in Review. Advance online publication. https://doi.org/10.1097/CRD.0000000000000940 (Review: Dual benefits for glycemic and weight control.)

[10] Frias, J. P., Davies, S., Eng, L., Mastrandrea, S., Karsbøl, F. K., ... & Davies, M. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720-730. https://doi.org/10.1016/S0140-6736(23)01163-7 (Phase 2: 15.6% loss vs. semaglutide alone.)

[11] Garvey, W. T., & REDEFINE 1 Study Group. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine, 393(7), 635-647.https://doi.org/10.1056/NEJMoa2502081 (REDEFINE 1: 22.7% loss over 68 weeks.)

[12] D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024 Jan-Feb 01;32(1):83-90. https://doi.org/10.1097/CRD.0000000000000513. Epub 2023 Oct 20. PMID: 36883831.

[13] Youmshajekian, L. (2025, March 4). Most people stop Ozempic after two years. What happens to weight and health? Scientific American. https://www.scientificamerican.com/article/does-stopping-ozempic-cause-rebound-weight-gain-and-health-problems/

[14] Sidrak WR, Kalra S, Kalhan A. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. Indian J Endocrinol Metab. 2024 Sep-Oct;28(5):445-460. https://doi.org/10.4103/ijem.ijem_442_23. Epub 2024 Sep 4. PMID: 39676791; PMCID: PMC11642516.